Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-09-12

FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SUBLOCADE (buprenorphine) from Indivior Inc., updating the product labeling as part of a supplemental filing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUBLOCADE (buprenorphine extended-release)

Snippet

SUPPL AP for SUBLOCADE (BUPRENORPHINE)